New Leaf - Morgans Valuation and Growth, page-3

I came up with 1.20 cash flow valuation and my average is around 70c

Other things to consider that may be beneficial to share price:

- News of class action against shine being dropped as not financially feasible, or being settled for a low payout covered by directors insurance.

- The decision on the pelvic mesh class action should be given by the judge within the next 9 months. The j&j hip replacement class action settled for 250m and that really helped shines cashflow and de-risked a lot of WIP to cash. Settlement of the mesh class action could easily be in the 400m+ range as most commentators agree, so this is significant financially for the company.

- Emerging practice revenue continuing to grow. Glad to see this continuing as it derisks revenue sources, possible law reform in the PI space, possibly moving into higher margin areas of law.

- The PFAS class actions. Currently five class actions being investigated or underway around australia. A settlement in one of these and the accused party (ADF, ect, basically the australian federal government) may well decide to quickly settle the rest to avoid court costs and bad publicity. Ie shine could see a domino effect where they generate some WIP for one case but the margins improve for the others if they settle early.